1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Ronald Buckanovich: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Vismodegib, Atezolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | Recruiting | Ronald Buckanovich | 48 | 2023-05-15 | 2026-06-18 |
| Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer ribociclib, Paclitaxel, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Ronald Buckanovich | 35 | 2017-06-10 | 2022-09-07 |
Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Carboplatin (1) · HhAntag691 (1) · Paclitaxel (1) · atezolizumab (1) · ribociclib (1)
United States (2)
Lan G Coffman, M.D. (1) · Ronald J Buckanovich, MD (1)